

Biotechnology Fund
SCHEDULE OF INVESTMENTS (Unaudited)

June 30, 2019

	Shares	Value
COMMON STOCKS[†] - 99.5%		
Biotechnology - 71.0%		
Amgen, Inc.	71,938	\$ 13,256,735
Gilead Sciences, Inc.	169,929	11,480,403
Celgene Corp.*	106,557	9,850,129
Illumina, Inc.*	25,373	9,341,070
Vertex Pharmaceuticals, Inc.*	47,048	8,627,662
Biogen, Inc.*	36,117	8,446,683
Regeneron Pharmaceuticals, Inc.*	23,448	7,339,224
Alexion Pharmaceuticals, Inc.*	53,048	6,948,227
Incyte Corp.*	62,102	5,276,186
Exact Sciences Corp.*	41,860	4,941,154
BioMarin Pharmaceutical, Inc.*	57,239	4,902,520
Seattle Genetics, Inc.*	59,538	4,120,625
Sage Therapeutics, Inc.*	21,026	3,849,650
Ionis Pharmaceuticals, Inc.*	58,438	3,755,810
Alnylam Pharmaceuticals, Inc.*	47,980	3,481,429
Bluebird Bio, Inc.* ¹	27,220	3,462,384
Exelixis, Inc.*	149,508	3,194,986
Amarin Corporation plc ADR* ¹	131,770	2,555,020
FibroGen, Inc.*	55,427	2,504,192
ACADIA Pharmaceuticals, Inc.*	92,859	2,482,121
Spark Therapeutics, Inc.*	24,016	2,458,758
Ultragenyx Pharmaceutical, Inc.*	38,590	2,450,465
United Therapeutics Corp.*	30,096	2,349,294
Immunomedics, Inc.* ¹	153,726	2,132,180
Medicines Co.*	57,196	2,085,938
PTC Therapeutics, Inc.*	46,240	2,080,800
Intercept Pharmaceuticals, Inc.*	25,219	2,006,676
Myriad Genetics, Inc.*	70,043	1,945,795
Ligand Pharmaceuticals, Inc. — Class B*	16,721	1,908,702
REGENXBIO, Inc.*	33,380	1,714,731
Total Biotechnology		140,949,549
Pharmaceuticals - 25.2%		
AbbVie, Inc.	175,023	12,727,673
Sarepta Therapeutics, Inc.*	30,198	4,588,586
Array BioPharma, Inc.*	86,703	4,016,950
Neurocrine Biosciences, Inc.*	41,329	3,489,408
PRA Health Sciences, Inc.*	32,830	3,255,095
Jazz Pharmaceuticals plc*	22,655	3,229,697
Nektar Therapeutics*	89,559	3,186,509
Alkermes plc*	110,800	2,497,432
Agios Pharmaceuticals, Inc.*	42,818	2,135,762
Global Blood Therapeutics, Inc.*	37,943	1,995,802
Supernus Pharmaceuticals, Inc.*	52,205	1,727,463
Portola Pharmaceuticals, Inc.*	63,080	1,711,360
Madrigal Pharmaceuticals, Inc.*	15,320	1,605,689
Heron Therapeutics, Inc.*	83,010	1,543,156
Spectrum Pharmaceuticals, Inc.*	146,092	1,257,852
Clovis Oncology, Inc.*	75,830	1,127,592
Total Pharmaceuticals		50,096,026
Healthcare-Products - 1.8%		
Bio-Techne Corp.	16,798	3,502,215
Healthcare-Services - 1.5%		
Syneos Health, Inc.*	57,790	2,952,491
Total Common Stocks (Cost \$96,869,681)		197,500,281
RIGHTS^{†††} - 0.0%		
Clinical Data, Inc.* ²	24,000	—
Total Rights (Cost \$—)		—
Face Amount		
REPURCHASE AGREEMENTS^{††3} - 0.6%		
JPMorgan Chase & Co. issued 06/28/19 at 2.53% due 07/01/19	\$ 799,767	799,767
Bank of America Merrill Lynch issued 06/28/19 at 2.48% due 07/01/19	198,676	198,676
Barclays Capital issued 06/28/19 at 2.40% due 07/01/19	198,676	198,676
Total Repurchase Agreements (Cost \$1,197,119)		1,197,119
Shares		
SECURITIES LENDING COLLATERAL^{†,4} - 1.6%		
Money Market Fund		
First American Government Obligations Fund — Class Z, 2.26% ⁵	3,182,615	3,182,615
Total Securities Lending Collateral (Cost \$3,182,615)		3,182,615
Total Investments - 101.7% (Cost \$101,249,415)		
	\$	201,880,015
Other Assets & Liabilities, net - (1.7)%		
		(3,405,377)
Total Net Assets - 100.0%	\$	198,474,638

* Non-income producing security.

[†] Value determined based on Level 1 inputs.

^{††} Value determined based on Level 2 inputs.

^{†††} Value determined based on Level 3 inputs.

¹ All or a portion of this security is on loan at June 30, 2019.

² Security was fair valued by the Valuation Committee at June 30, 2019. The total market value of fair valued securities amounts to \$0, (cost \$0) or 0.0% of total net assets.

³ Repurchase Agreements.

⁴ Securities lending collateral.

⁵ Rate indicated is the 7-day yield as of June 30, 2019.

ADR — American Depositary Receipt
plc — Public Limited Company